Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 22.82 Billion | USD 67.50 Billion | 11.6% | 2024 |
The global cancer biomarkers market size was worth around USD 22.82 Billion in 2024 and is predicted to grow to around USD 67.50 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 11.6% between 2025 and 2034. The report analyzes the global cancer biomarkers market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the cancer biomarkers industry.
Cancer biomarkers are biological molecules that are produced by tumor cells or human tissues in response to cancer and are then measured and evaluated as indicators of cancerous processes within the body. Cancer biomarkers are widely used in the detection and management of cancer patients. Biomarkers are used in the follow-up surveillance and early detection of possible recurrent disease in cancer patients who have undergone curative surgery. Furthermore, ongoing advancements in cancer diagnosis include the incorporation of molecular biomarkers into routine diagnostic tests. Various governments are focusing on investing in cancer prevention and early intervention in order to reduce the emotional and physical impact of cancer on patients and their families. Furthermore, national healthcare departments are actively involved in cancer research and treatment development. The rising cancer incidence is expected to spur innovation and development in the field of cancer diagnosis using biomarkers.
The rising prevalence of cancer, particularly lung cancer, around the world is one of the major factors driving market value growth. Rising R&D spending on medical instruments and devices, especially in developed and developing economies, will open up even more lucrative market growth opportunities. Research and development capabilities for drug discovery are also boosting market growth rates. The federal government's increased funding is expected to drive the market's growth rate. Furthermore, the growth and expansion of the healthcare industry, driven by both public and private players, will create lucrative personal health devices market growth opportunities, particularly in developing economies.
Drivers: Technological advancements on the rise In the creation of cancer biomarkers
Advances in array and proteomics technologies have addressed the difficulties in identifying and comprehending the functions and interactions of various proteins. These technological advancements have greatly simplified the process of discovering and developing novel cancer biomarkers.
Restraint: Sample collection-related technical issues
One of the most important issues for service providers is sample collection, which is followed by access to these samples. These samples must be subjected to strict quality control, and they must be stored in the proper conditions to avoid loss. Furthermore, various samples are required for risk detection, screening, diagnosis, and monitoring processes.
Personalized medicine determines the best course of treatment for individual patients. Cancer biomarkers are crucial in certain aspects of personalized medicine. Cancer biomarker testing consumables allow for the identification of these diseases. Cancer biomarker diagnostics are also used as companion diagnostics for a number of experimental therapies. As a result, the field of personalized medicine is expected to provide potential growth opportunities for cancer biomarkers market participants.
Challenges: Challenges associated with cancer biomarker validation
The process of cancer biomarker validation includes evaluating assays or measuring performance characteristics such as sensitivity, specificity, and reproducibility. Validation is essential for establishing cancer biomarkers as trustworthy tools to aid in development, medical care, and biopharma investment decisions.
The global Cancer Biomarkers market is segregated based on Biomarkers Type, Cancer Type, Profiling Technologies and application.
Based on Biomarkers Type, the market is segmented into Protein Biomarkers, Genetic Biomarkers and Other Cancer Biomarkers. Protein biomarkers accounted for the largest share of the cancer biomarker market, owing primarily to technological advancements. In the development of cancer biomarkers and the expansion of cancer biomarker research and development.
On the basis of Cancer Type, the global cancer biomarkers market is bifurcated into Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin's Lymphoma, Kidney Cancer and Other Cancer Types.
By Profiling Technologies, the global cancer biomarkers market is split into Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics and Cytogenetics.
Based on application, the market is segmented into Diagnostics, Research & Development, Prognostics, Risk Assessment and Other Applications. The diagnostics segment held the lion's share of the cancer biomarkers market. The increasing use of cancer biomarkers in drug discovery and development, as well as increased cancer biomarker R&D, are driving the growth of this segment.
Report Attributes | Report Details |
---|---|
Report Name | Cancer Biomarkers Market |
Market Size in 2024 | USD 22.82 Billion |
Market Forecast in 2034 | USD 67.50 Billion |
Growth Rate | CAGR of 11.6% |
Number of Pages | 140 |
Key Companies Covered | F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc (US), QIAGEN N.V. (Netherlands), Illumina Inc (US), Bio-Rad Laboratories Inc (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics Inc (US), Sysmex Corporation (Japan), Hologic Inc (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer Inc (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems Inc (US), BioVision Inc (US), Olink (Sweden), Asuragen Inc (US), Meso Scale Diagnostics, LLC (US), Invivoscribe Inc (US), Seegene Technologies Inc (South Korea), and others. |
Segments Covered | By Biomarkers Type, By Cancer Type, By Profiling Technologies, By Application, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America dominates the cancer biomarkers market due to its strong base of healthcare facilities, rising investment from key players in the development of advanced devices, increasing number of processes pertaining to drug development, detection of specific tumors, monitoring biological response to cancer therapy, and rising number of research activities.
Asia-Pacific is expected to grow significantly between 2022 and 2028, owing to an increase in government initiatives to raise awareness, an increase in medical tourism, increased research activities in the region, rising cancer prevalence, and a growing demand for quality healthcare in the region.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the cancer biomarkers market on a global and regional basis.
The global cancer biomarkers market is dominated by players like:
By Biomarkers Type
By Cancer Type
By Profiling Technologies
By Application
By Region
FrequentlyAsked Questions
North America is expected to dominate the cancer biomarkers market over the forecast period.
Leading players in the global cancer biomarkers market include F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc (US), QIAGEN N.V. (Netherlands), Illumina Inc (US), Bio-Rad Laboratories Inc (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics Inc (US), Sysmex Corporation (Japan), Hologic Inc (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer Inc (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems Inc (US), BioVision Inc (US), Olink (Sweden), Asuragen Inc (US), Meso Scale Diagnostics, LLC (US), Invivoscribe Inc (US), Seegene Technologies Inc (South Korea), among others.
The report explores crucial aspects of the cancer biomarkers market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed